Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in CIDP
NCT07540221Phase 3Recruiting
- Sponsor
- Grifols
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 4
01
Overview
A Phase 3 trial of immune globulin subcutaneous, human-klhw in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by Grifols. Started Apr 2026; status: recruiting.
02
Drugs
immune globulin subcutaneous, human-klhw
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT07540221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540221.